MEDiC Life Sciences enters research collaboration with Bristol Myers Squibb
Posted on July 17th, 2023
MEDiC Life Sciences announced it has entered a research collaboration with Bristol Myers Squibb to identify novel oncology targets using MEDiC’s functional CRISPR genomics platform.
MEDiC will use its scalable 3-dimensional tumor models to perform CRISPR functional genomics screens in solid tumor indications of interest to Bristol Myers Squibb. MEDiC is also using its immune cell and tumor cell co-culture platform to identify novel genes relevant to immune cell killing of cancer cells.
The collaboration with Bristol Myers Squibb highlights the confidence and recognition that leading industry players have in MEDiC’s technology.
MEDiC Life Sciences was founded in 2020 based on discoveries advanced through SPARK at Stanford. MEDiC has developed a proprietary functional genomics platform including patient-tumor-like cancer models to identify optimal gene targets and biomarkers for solid cancer. The platform will enable genome-scale, unbiased and systematic discovery of novel drug targets for various solid tumor indications, by combining CRISPR functional genomics with 3D patient-tumor-like cancer models.
Co-founder and former SPARKee Kyuho Han, PhD, said, “We are very excited that Bristol Myers Squibb selected MEDiC as a collaborator to advance its oncology discovery programs. We look forward to working with Bristol Myers Squibb to identify novel oncology targets to advance potentially effective new medicines for cancer patients.”
To read more, view the press release here. For more information on MEDiC, visit its website.